Lancet Rheumatology

Article	Citations
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	870
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	842
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	304
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	189
A disseminated gonococcal infection with spinal locations	188
Biological disease-modification in axial spondyloarthritis: insights from MRI	133
Research in Brief	133
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	131
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	115
Can contextual factors improve clarity of the results from clinical trials of low back pain?	114
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	112
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	111
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	100
Reigniting the burnt-out health-care workforce	96
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	90
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	86
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	82
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	76
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	74
Women in rheumatology in Africa	70
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	66
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	66
Early-stage Dupuytren's disease treatment; a promising next step?	58
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	58
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	56

Pausing drugs and spacing vaccines: an open question – Authors' reply	56
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	55
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	54
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	46
Research in Brief	46
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	45
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	45
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	44
Composite endpoints for Sjögren's Syndrome	44
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	44
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	43
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	43
Biosimilars and the era of interchangeability	42
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	42
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42
Assessing glucocorticoid toxicity: are the measures sensitive enough?	42
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	42
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	41
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	41
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	41
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	40
Kanon Jatuworapruk: bringing out the enjoyment in life	39
Clinical trial design: time to accelerate the pace of change?	39
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study	38
Let's talk about sex in interstitial lung disease	38
Tackling heterogeneity in Sjögren's disease	37
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a p	37
Mental health before and during the pandemic in people with systemic sclerosis	37
Additional SARS-CoV-2 vaccine doses: a little is better than none	35
Clinical hypnosis and pain management in sharp debridement of skin ulcers in immune-mediated inflammatory diseases	34
Research in Brief	33
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	33
Urgent reform needed for homecare medicines services	33
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19	32
Optimal non-opioid analgesic combinations after total hip arthroplasty – Authors' reply	32
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	32
Constitutional symptoms of severe childhood-onset polyarteritis nodosa	31
Global access to biological disease-modifying drugs	30
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study	30
COVID-19: is the rush to boost backed by science?	29
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies	29
Who will respond to type I interferon receptor blockade in SLE?	29
Research in Brief	29
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	29
The 2024 US election—voting for equitable health care	28
Challenges in the therapeutic management of psoriatic arthritis	28
Call for papers: Sex and gender in rheumatology	27
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases	26
Are we ready for home spirometry for systemic sclerosis-associated ILD?	26
Advancing research and equity through collaboration	26

Suspending methotrexate for 2 weeks after COVID-19 vaccination	26
Sex differences of brain oscillatory activity and quantitative sensory testing in people with chronic osteoarthritis pain: a cross-sectional study	26
Explanation for substandard of care comparators in rheumatology randomised trial protocols	25
Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal	25
Digital self-management for back pain in the UK	24
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	24
JIA care under the microscope	24
Telemedicine: is the new normal fit for purpose?	24
Cranial involvement in giant cell arteritis	24
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national co	23
Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5	23
Enabling and supporting public and patient involvement in arthritis research	23
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	23
Better diagnostic tools needed for biopsy-negative giant cell arteritis	23
Intra-articular botulinum toxin A injection for painful base-of-thumb osteoarthritis: a double-blind, randomised, controlled, phase 3 trial (RHIBOT)	23
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	23
The impact of COVID-19 on care of early inflammatory arthritis in the UK	22
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	22
Sex-related differences in health-care use in adult patients with inflammatory arthritis in Ontario, Canada: a population-based cohort study	22
For SLE activity and glucocorticoids: aim low	22
Polychondritis in a child	22
COP27 Climate Change Conference: urgent action needed for Africa and the world	22
Reconciling immunotherapy and autoimmunity: not for the faint of heart	22
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study	22
Jean Liew: from Bronte scholar to social media influencer	22
Pain and wellbeing in young people with arthritis	22
Penélope Palominos: rheumatology by sight and touch	22
Arthritis and fertility: time to think about men	22
Coronary polyarteritis nodosa	22
Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences	21
Microscopic polyangiitis presenting with retinal frosted branch angiitis	21
Beneficial side-effects of colchicine for patients with gout	21
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply	21
Gout in central Asia: a few things make a big difference	20
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses	20
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study	20
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	20
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study	20
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	19
Research in Brief	19
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study	19
David Liew: where communication meets medicine	19
Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case–control study	19
Ustekinumab with or without methotrexate for psoriatic arthritis?	18
Effectiveness of a fourth mRNA dose among individuals with systemic autoimmune rheumatic diseases during the Omicron era	18
Role of plasma exchange in ANCA-associated vasculitis – Authors' reply	18
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation – Authors' reply	18
Rheumatology congresses post COVID-19: we cannot regress	18
Research in Brief	18
DAVIX: a vascular outcome measure in systemic sclerosis	18
Correction to Lancet Rheumatol 2023; 5: e461–73	18
A role for interleukin-1 receptor antagonism in severe COVID-19?	18
Composite endpoints for Sjögren's Syndrome – Authors' reply	18
Digital remote monitoring in rheumatology: using health economics to support wider adoption	17
Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease	17
Thank you to our peer reviewers in 2021	16
Coronary polyarteritis nodosa in a young adult	16
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	16
Advancing predictive accuracy for shoulder replacement surgery	16
Time to revisit the therapeutic benefits of exercise for osteoarthritis?	16
Prevention of psoriatic arthritis: the next frontier	16
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study	16
Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial	15
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	15
Socioeconomic deprivation worsens rheumatoid arthritis	15
Prize trends in rheumatology: the Gender Award Gap	15
Research in Brief	15
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade	15
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities	15
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	15
Titilola (Lola) Falasinnu: looking out for the overlooked	14
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	14
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	13
How should we define disease and outcomes in axial psoriatic arthritis?	13
Vasculitis: the promising road ahead	13
Industry involvement in rheumatology consensus-based recommendations: a systematic review	13
Palliative care in patients with rheumatic diseases	13
Susac syndrome: challenges of interpreting treatment data in a rare disease	13
Research in Brief	13
Research in Brief	13

Research in Brief	13
Correction to Lancet Rheumatol 2022; 4: e177–87	12
The same genotype gives rise to a spectrum of disorders	12
The influence of safety warnings on the prescribing of JAK inhibitors	12
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study	12
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	12
Debate over interventional procedures for chronic spine pain	12
Cardiovascular risk in gout: time for action	12
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a	12
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	12
Rheumatic cognitive impairment: a new clinical entity?	12
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	12
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	12
Correction to Lancet Rheumatol 2022; 4: e853–63	12
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	12
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	12
Calcium pyrophosphate deposition disease	12
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	11
Predictors of pregnancy outcomes in SLE	11
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	11
Narendra Kumar Bagri: taking paediatric rheumatology in India to new heights	11
Michael Barrett: navigating hostile terrain	11
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply	11
Expanding role of biomarkers in characterising hyperinflammatory syndromes – Authors' reply	11
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	11
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial	11
Getting better at quantifying the toxicity of glucocorticoids	11
Predictors of pregnancy outcomes in SLE	11
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	11
Modelling allopurinol-induced severe adverse cutaneous reactions	10
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	10
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	10
Promise and challenges of mesenchymal stromal cell therapy in severe SLE	10
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	10
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	10
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study	10
Research in Brief	9
Long COVID in inflammatory rheumatic diseases—what's in a name?	9
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	9
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	9
Correction to Lancet Rheumatol 2021; 3: e789–97	9
Self-management of gout using a mobile app	9
Coronary polyarteritis nodosa in a young adult – Authors' reply	9
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis	9
Kimberly Templeton: creative change maker	9
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	9
Inclusion of pregnant populations in clinical trials in China: the ethical considerations	9
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?	9
Research in Brief	9
Debashish Danda	9
Contesting the BACPAP consortium's consensus – Authors' reply	9
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply	9
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	9
Aspirin desensitisation in pregnant individuals with autoimmune disease	9
Correction to Lancet Rheumatol 2022; 4: e262–73	9